Comparison
6q Terminal Deletion Syndrome C4304514 vs 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Clinical comparison between 6Q Terminal Deletion Syndrome and 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial for differential diagnosis and treatment planning.
6q Terminal Deletion Syndrome C4304514
A chromosomal disorder involving deletion of genetic material at the end of chromosome 6, leading to developmental delays and variable physical features.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
A partial form of enzyme deficiency affecting hormone production. Symptoms vary but may include hormonal imbalances and elevated blood pressure. Treatment usually involves hormone replacement and regular medical follow-up.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Variable
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
severe
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 17-alpha-hydroxylase-17-20-lyase-deficiency-combined-partial-C4017190 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | Discriminating power |
|---|---|---|---|
| Developmental pattern | Developmental delay and variable congenital features may be present from early life. | Primary presentation is hormonal imbalance rather than a chromosomal developmental syndrome. | High |
| Blood pressure | Hypertension is not an established defining feature from the supplied description. | Elevated blood pressure may occur, but severity and timing are variable. | Moderate |
| Sex-hormone related findings | Not specifically established by the supplied source description. | Partial enzyme deficiency may disrupt sex-steroid and cortisol-related pathways. | High |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Congenital developmental concerns
A chromosomal evaluation is more relevant when early developmental delay and variable physical features suggest a genetic syndrome.
High
Suspected terminal 6q deletion
Genetic testing can assess deletion of material at the end of chromosome 6.
High
No dominant endocrine phenotype
Absence of a hormone-centered presentation makes the enzyme deficiency less likely, but does not exclude it.
Low
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 when
Hormonal imbalance with hypertension
This combination better matches the described partial enzyme deficiency, pending endocrine confirmation.
Moderate
Suspected steroidogenic defect
Specialist hormone testing is appropriate when cortisol or sex-steroid production is questioned.
High
Variable-age endocrine presentation
Onset is described as variable, unlike the congenital onset pattern supplied for the deletion syndrome.
Moderate
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify a terminal deletion of chromosome 6. | Not expected to diagnose this enzyme deficiency. | A genetic result requires laboratory and clinician confirmation. |
| Steroid hormone profile | No characteristic profile is established here. | May show abnormalities reflecting partial 17α-hydroxylase/17,20-lyase deficiency. | Abnormal hormones are findings, not a standalone diagnosis. |
| Blood pressure measurement | No specific pattern is established by the source. | Elevation may be found but is not universally defined. | Results need clinical context and repeated assessment. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- A chronic congenital condition with variable developmental and physical effects; exact outcomes are not established here.
- Factors
- Deletion extent, associated features, developmental support, and comorbidities may influence course.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
- Outcome
- A chronic partial endocrine deficiency whose course varies; outcomes are not quantified here.
- Factors
- Degree of enzyme impairment, blood pressure, hormone balance, and follow-up may matter.
Time frame: Both are described as chronic; deletion features begin congenitally, while endocrine onset is variable.
Individual prognosis requires clinician assessment and should not be inferred from this comparison.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impairment | Delays are described and may affect learning or function. Not a defining feature in the supplied description. Support needs vary and are not predictable from these data. |
| Hormonal deficiency | Not established as characteristic. Partial hormone production defects may require replacement and monitoring. Treatment details and doses are not specified here. |
| Hypertension-related risk | Not established from the source. Elevated blood pressure may contribute to clinical risk. Magnitude and outcomes are not established here. |
Patient education highlights
- HighDifferent causes
One condition is a chromosomal deletion; the other is a partial enzyme deficiency affecting hormones.
- HighSpecialist follow-up
Genetic or endocrine findings should be interpreted by qualified clinicians, with regular follow-up when indicated.
- MediumVariable features
Symptoms and physical findings can vary; an abnormal test does not by itself confirm either diagnosis.